Global RNA Interference (RNAi) Therapy Market Sales Revenue Opportunity Report 2018

The popularity of RNAi technology has been increasing in recent times as is has become a major component of basic research, and in drug discovery. Over the years this technology has become an integral part of the process of determining the functions of gene, in analyzing pathways, and in the validation of the target both in academia and in industry.

Download Report:

https://www.kuickresearch.com/report-Global-RNA-Interference-(RNAi)-Therapy-Market-Outlook-2018.php

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

"Global RNA Interference (RNAi) Therapy Market Outlook 2018" Table of Contents

1. Introduction to RNA Interference (RNAi) Therapy
1.1 Need for RNAi Therapy
1.2 RNAi Technologies

2. Benefits of RNA Interference (RNAi) Therapy

3. RNA Interference (RNAi) Drug Delivery Mechanics
3.1 Role of RNAi in Target Validation
3.2 Role of RNAi in Target Identification

4. Global RNA Interference (RNAi) Therapy Market Overview
4.1 Regional Markets
4.2 Ongoing RNAi Therapy Clinical Trial

5. Global RNA Interference (RNAi) Market Dynamics
5.1 Favorable Market Drivers
5.2 Challenges to be Addressed
5.3 Future Growth Opportunities

6. RNAi Clinical Pipeline by Phase, Indication & Country
6.1 Unknown Phase
6.2 Research
6.3 Preclinical
6.4 Phase-I
6.5 Phase I/II
6.6 Phase-II
6.7 Phase-III

7. Suspended & Discontinued RNAi Profiles
7.1 No Development Reported
7.2 Discontinued
7.3 Suspended

8. Competitive Landscape
8.1 Arrowhead Research
8.2 Alnylam Pharmaceuticals
8.3 Benitec Biopharma
8.4 Dicerna Pharmaceuticals
8.5 InteRNA Technologies
8.6 Isis Pharmaceuticals
8.7 RXi Pharmaceuticals
8.8 Santaris Pharma
8.9 Silence Therapeutics
8.10 Tekmira Pharmaceuticals Corporation

Figure 4-1: Global RNAi Therapy Market (US$ Billion), 2012-2018
Figure 4-2: RNAi Therapy Market by Region, 2013
Figure 4-3: Global RNAi Drug Clinical Pipeline by Phase (%), 2014
Figure 4-4: Global RNAi Drug Clinical Pipeline by Phase (Number of Drugs), 2014
Figure 4-5: Suspended & Discontinued RNAi Drug in Clinical Pipeline (%), 2014
Figure 4-6: Suspended & Discontinued RNAi Drug in Clinical Pipeline (Number of Drugs), 2014
Figure 4-7: Discontinued RNAi Drug Clinical Pipeline by Phase (%), 2014
Figure 4-8: Discontinued RNAi Drug Clinical Pipeline by Phase (Number of Drugs), 2014
Figure 4-9: Suspended RNAi Drug Clinical Pipeline by Phase (%), 2014
Figure 4-10: Suspended RNAi Drug Clinical Pipeline by Phase (Number of Drugs), 2014

List of Tables

Table 8-1: Arrowhead Research Corporation RNAi Pipeline
Table 8-2: Alnylam Pharmaceuticals RNAi Pipeline
Table 8-3: Benitec Biopharma RNAi Pipeline
Table 8-4: Dicerna Pharmaceuticals RNAi Pipeline
Table 8-5: InteRNA Technologies RNAi Pipeline
Table 8-6: Isis Pharmaceuticals RNAi Pipeline
Table 8-7: RXi Pharmaceuticals Corporation RNAi Pipeline
Table 8-8: Santaris Pharma RNAi Pipeline
Table 8-9: Silence Therapeutics RNAi Pipeline
Table 8-10: Tekmira Pharmaceuticals RNAi Pipeline

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.